SPEAR PHARMACEUTICALS

For more than 25 years, Spear Pharmaceuticals has been committed to making FDA-approved bioequivalent and branded products accessible to the public. The Spear doctrine for bioequivalent drugs is to utilize the same active and inactive ingredients, as well as the same texture, look and consistency, as the branded product. Their commitment to quality has resulted in FDA approval of eleven first-to-market bioequivalent dermatological products, with several more in the pipeline.